Toronto, Ontario – The Newswire – October 12, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) has been accepted as a lead sponsor at the British Society of Echocardiography’s (BSEcho) annual conference to demonstrate its use of Artificial Intelligence to create MRI-quality model of the heart from ultrasound images.
The highly anticipated hybrid conference in Cardiff, UK will bring together renowned experts and professionals in the field of echocardiography from Oct. 13th to 14th. The BSEcho is the leading global forum for the study and advancement of ultrasound imaging and Doppler techniques in cardiology.
“We continue to place Ventripoint’s AI technology before the world’s leaders in the treatment of cardiovascular disease,” said Ventripoint President & CEO, Dr. Avira Macanovic. “This is an elite audience that will appreciate our ability to turn ultrasound images into a MRI-quality model of the heart, at a speed and cost never before possible.”
Some of the topics discussed this year at the BSEcho will the use of AI in routine scans, LV functional assessment, musculoskeletal health, stress echocardiography, and much more.
As a gold sponsor, Ventripoint Diagnostics will have a prominent presence at the BSEcho Conference with an interactive booth in the main hall. The booth will give attendees an opportunity to learn about the VMS+ 3.0 system, engage in hands-on demonstrations, and interact with the Ventripoint team to gain deeper insights into the technology and clinical applications. Ventripoint will also have designated sponsorship activities such as direct emails to members, social media broadcasts, and inclusion to Echo eNews.
This is the second year that Ventripoint has been highlighted in the meeting, demonstrating its commitment to advancing cardiovascular diagnostics and its dedication to supporting the scientific community. The company is excited to collaborate with leading experts and thought leaders at the conference and play a role in improving research and patient outcomes.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Jonathan Robinson
This email address is being protected from spambots. You need JavaScript enabled to view it.
416-669-1001
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
